These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32113823)

  • 1. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Zhang LY; Qu XN; Sun ZY; Zhang Y
    Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
    Feng WH; Bi Y; Li P; Yin TT; Gao CX; Shen SM; Gao LJ; Yang DH; Zhu DL
    J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I; Selph S
    Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
    Deng M; Wen Y; Yan J; Fan Y; Wang Z; Zhang R; Ren L; Ba Y; Wang H; Lu Q; Fan H
    BMC Med; 2023 Nov; 21(1):447. PubMed ID: 37974258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
    Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
    Petit JM; Cercueil JP; Loffroy R; Denimal D; Bouillet B; Fourmont C; Chevallier O; Duvillard L; Vergès B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):407-415. PubMed ID: 27732328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
    Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
    J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
    Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
    Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
    Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
    Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
    Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
    Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
    Zhang L; Wu X; Li X; Chang X; Ding X; Wang Q; Jiang T; Wang G; Liu J
    Acta Diabetol; 2023 Jul; 60(7):971-979. PubMed ID: 37079136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.
    Yoneda M; Kobayashi T; Honda Y; Ogawa Y; Kessoku T; Imajo K; Nogami A; Taguri M; Kirikoshi H; Saito S; Nakajima A
    Hepatol Commun; 2022 Sep; 6(9):2273-2285. PubMed ID: 35578445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.